UA35588C2 - Засіб для лікування десинхронізаційних порушень та фармацевтична композиція - Google Patents

Засіб для лікування десинхронізаційних порушень та фармацевтична композиція

Info

Publication number
UA35588C2
UA35588C2 UA94119022A UA94119022A UA35588C2 UA 35588 C2 UA35588 C2 UA 35588C2 UA 94119022 A UA94119022 A UA 94119022A UA 94119022 A UA94119022 A UA 94119022A UA 35588 C2 UA35588 C2 UA 35588C2
Authority
UA
Ukraine
Prior art keywords
melatonin
treating
agent
pharmaceutical composition
acetyl
Prior art date
Application number
UA94119022A
Other languages
English (en)
Russian (ru)
Inventor
Майкл Едвард Фло
Майкл Эдвард Фло
Original Assignee
Елі Ліллі Енд Компані
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Елі Ліллі Енд Компані, Эли Лилли Энд Компани filed Critical Елі Ліллі Енд Компані
Publication of UA35588C2 publication Critical patent/UA35588C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Винахід належить до нового способу лікування у ссавців десинхронізаційних порушень, а також до призначених для цього фармацевтичних композицій. Мелатонін, представлений нижченаведеною формулою: має систематичну назву N-[2-(5-метокси-3-індоліл) етил]ацетамід. Тривіальними назвами сполуки є N-ацетил-5-метокситриптамін і N-ацетил-О-метилсеротонін. Мелатонін є гормоном шишковидного тіла, який інгібує овуляцію, а також інгібує ріст клітин МCF-7 раку молочної залози людини і може застосовуватись для лікування раку молочної залози у ссавців.
UA94119022A 1993-11-18 1994-11-14 Засіб для лікування десинхронізаційних порушень та фармацевтична композиція UA35588C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/154,903 US6180657B1 (en) 1993-11-18 1993-11-18 Melatonin derivatives for use in treating desynchronization disorders

Publications (1)

Publication Number Publication Date
UA35588C2 true UA35588C2 (uk) 2001-04-16

Family

ID=22553300

Family Applications (1)

Application Number Title Priority Date Filing Date
UA94119022A UA35588C2 (uk) 1993-11-18 1994-11-14 Засіб для лікування десинхронізаційних порушень та фармацевтична композиція

Country Status (21)

Country Link
US (1) US6180657B1 (uk)
EP (1) EP0656209B1 (uk)
JP (1) JPH07196504A (uk)
KR (1) KR950013509A (uk)
CN (1) CN1100533C (uk)
AT (1) ATE239470T1 (uk)
AU (1) AU7777694A (uk)
CA (1) CA2135710C (uk)
CZ (1) CZ288834B6 (uk)
DE (1) DE69432626T2 (uk)
DK (1) DK0656209T3 (uk)
ES (1) ES2197904T3 (uk)
HU (1) HUT72070A (uk)
IL (1) IL111579A (uk)
NO (1) NO307364B1 (uk)
NZ (1) NZ264893A (uk)
PT (1) PT656209E (uk)
RU (1) RU2160101C2 (uk)
SG (1) SG77569A1 (uk)
UA (1) UA35588C2 (uk)
ZA (1) ZA948928B (uk)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0748627A3 (en) * 1995-06-14 1997-05-21 Lilly Co Eli Melatonin agonists for the treatment of benign forms of hyperplasia of the prostate
CA2551117A1 (en) * 2003-12-23 2005-07-14 Abraxis Bioscience, Inc. Substituted melatonin derivatives, process for their preparation, and methods of use
AR061478A1 (es) * 2006-06-19 2008-08-27 Takeda Pharmaceutical Compuesto triciclico y composicion farmaceutica
CA2724782A1 (en) * 2008-05-19 2009-11-26 Takeda Pharmaceutical Company Limited An anti-cancer cytotoxic monoclonal antibody
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR20180100450A (ko) 2012-01-26 2018-09-10 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
MX2015007909A (es) 2012-12-18 2016-04-25 Vanda Pharmaceuticals Inc Tratamiento de trastornos del ritmo circadiano.
RU2533965C1 (ru) * 2013-07-04 2014-11-27 Государственное бюджетное учреждение здравоохранения "Самарский областной гериатрический центр" Способ нормализации циркадианных ритмов человека
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
RU2655813C1 (ru) * 2017-06-09 2018-05-29 Федеральное государственное бюджетное учреждение науки "Институт токсикологии Федерального медико-биологического агентства" Средство коррекции и профилактики состояний, вызванных нарушением суточных ритмов

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087444A (en) 1976-09-08 1978-05-02 Eli Lilly And Company Amides as ovulation inhibitors
US4600723A (en) 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
EP0126630B1 (en) * 1983-05-18 1987-09-16 Monash University The use of melatonin for the manufacture of a medicament
US4614807A (en) 1984-10-04 1986-09-30 Eli Lilly And Company 6,7-dihalomelatonins
US4687763A (en) 1985-02-25 1987-08-18 Massachusetts Institute Of Technology Composition and method for increasing levels or release of brain serotonin
IL79264A0 (en) 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
US4997845A (en) 1987-02-02 1991-03-05 Eli Lilly And Company β-alkylmelatonins as ovulation inhibitors
WO1989001472A1 (en) 1987-08-17 1989-02-23 Nelson Research & Development Co. Melatonin analogues
US5093352A (en) 1988-11-14 1992-03-03 Whitby Research, Inc. Antidepressant agents
JPH0418034A (ja) * 1990-05-11 1992-01-22 Kanegafuchi Chem Ind Co Ltd 点眼組成物
US5242941A (en) 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
IT1251544B (it) 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
ZA928011B (en) * 1991-10-18 1993-06-23 Alza Corp Transdermal administration of melatonin.
US5196435A (en) 1991-11-21 1993-03-23 Eli Lilly And Company Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma
IT1254995B (it) * 1992-06-24 1995-10-11 Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
IT1255199B (it) * 1992-07-01 1995-10-20 Franco Fraschini Farmaco sintetizzato analogo della melatonina particolarmente efficacenelle patologie che interferiscono con i ritmi circadiani
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin

Also Published As

Publication number Publication date
DK0656209T3 (da) 2003-09-01
PT656209E (pt) 2003-09-30
NO307364B1 (no) 2000-03-27
CZ276494A3 (en) 1995-07-12
HU9403299D0 (en) 1995-01-30
IL111579A (en) 1999-10-28
NZ264893A (en) 1997-06-24
EP0656209A3 (en) 1995-10-11
DE69432626D1 (de) 2003-06-12
ATE239470T1 (de) 2003-05-15
CA2135710C (en) 2007-07-10
NO944340D0 (no) 1994-11-14
CZ288834B6 (cs) 2001-09-12
HUT72070A (en) 1996-03-28
RU94041028A (ru) 1996-09-20
IL111579A0 (en) 1995-01-24
CN1100533C (zh) 2003-02-05
CA2135710A1 (en) 1995-05-19
EP0656209B1 (en) 2003-05-07
SG77569A1 (en) 2001-01-16
AU7777694A (en) 1995-05-25
JPH07196504A (ja) 1995-08-01
CN1107700A (zh) 1995-09-06
NO944340L (no) 1995-05-19
DE69432626T2 (de) 2004-04-08
RU2160101C2 (ru) 2000-12-10
US6180657B1 (en) 2001-01-30
ES2197904T3 (es) 2004-01-16
EP0656209A2 (en) 1995-06-07
ZA948928B (en) 1996-05-10
KR950013509A (ko) 1995-06-15

Similar Documents

Publication Publication Date Title
PT804252E (pt) Agentes queladores metalicos que contem monoaminas diamidas e tiois
DE3568272D1 (en) 4-vinylbenzoic-acid derivatives, their preparation and their use as therapeutical compositions and as ligands
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
EG20001A (en) Process for preparing of novel hydrox-amic acid and N-hydroxyurea derivatives and their use
BG102600A (en) Carbamoyloxy derivatives of mutilin and their use as bactericides
HK1011685A1 (en) Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
ATE206611T1 (de) Verwendung von mangiferin oder seinen derivaten zur kosmetischen anwendung
DE69430440D1 (de) Zusammensetzungen zur inhibition von retroviraler verbreitung, die 2',3'-dideoxy-inosin und hydroxyharnstoff enthalten
MY115339A (en) Compositions containing micronized nebivolol
DE69132048T2 (de) Verwendung von Steroiden zur Inhibierung von Angiogenesis
UA35588C2 (uk) Засіб для лікування десинхронізаційних порушень та фармацевтична композиція
MX9706647A (es) Composiciones farmaceuticas que comprenden inhibidores de oxidasa b de monoamina.
HU9402933D0 (en) Neurotensine-receptor-active 1-naphtyl-pyrazol-3-carboxamides process for producing them and pharmaceutical compositions containing them as active components
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
GB9418912D0 (en) Pharmaceutically active compounds
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
ATE152628T1 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
PL316656A1 (en) Free halophantrin base for use in treating marsh-fever and compositions containing same
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
DE69521037D1 (de) Chinazolinylamino derivate mit alfa-antagonist wirkung
YU13599A (sh) Primena farmaceutske kompozicije za dobijanje leka u obliku gela
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
ZA90962B (en) Phenylhydrazones,the manufacture thereof and therapeutic and cosmetic compositions prepared therefrom
LV11272A (lv) Terapeitiska kompozicija